Patents
US 12714722 B2: Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
- Granted
- 2026-08-25
- Filed
- 2020-03-20 application 17441599
- Type
- Utility · 10 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor in combination with a nicotinamide adenine dinucleotide (NAD) salvage pathway precursor are described. Cancers treated with the combination therapies can be nicotinamide riboside kinase (NMRK1) low cancers and/or Myc high cancers and can include various forms of glioblastomas.
Source: PTBLXML, file of 2026-08-25 (ipgb20260825.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Fred Hutchinson Cancer Center 81 patents | US company or organization | Seattle, WA | FRED HUTCHINSON CANCER CENTER Nonprofit EXACT high confidence: identical full name and state | PTBLXML, file of 2026-08-25 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| David Hockenbery | Seattle, WA | PTBLXML, file of 2026-08-25 | ||
| Patrick Paddison | Seattle, WA | PTBLXML, file of 2026-08-25 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/706 | PTBLXML, file of 2026-08-25 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P35/00 | PTBLXML, file of 2026-08-25 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2022-11-04 | Correction Corrective assignment to correct the patent application number 63/242,906 previously recorded on reel 060439 frame 0279. assignor(s) hereby confirms the merger and change of name. | FRED HUTCHINSON CANCER RESEARCH CENTER signed 2022-04-01 SEATTLE CANCER CARE ALLIANCE signed 2022-04-01 | FRED HUTCHINSON CANCER CENTER SEATTLE, WA | 61847/594 | PASDL, file of 2026-10-15 |
| 2022-06-23 | Merger Merger and change of name | FRED HUTCHINSON CANCER RESEARCH CENTER signed 2022-04-01 SEATTLE CANCER CARE ALLIANCE signed 2022-04-01 | FRED HUTCHINSON CANCER CENTER SEATTLE, WA | 60439/279 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.